AN2 Therapeutics reports Q4 2022 net loss $11.8M, full year loss $41.0M; cash $99.3M

AN2 Therapeutics, Inc.

Net loss for Q4 2022 was $11.8M and full year 2022 was $41.0M.
R&D expenses for full year 2022 were $29.5M vs $16.9M in 2021; G&A $12.8M vs $4.7M.
Cash, cash equivalents and investments totaled $99.3M at Dec 31, 2022, expected to fund through mid-2024.
Phase 2/3 pivotal trial for epetraborole in MAC lung disease approaching 60 sites; Phase 2 enrollment expected to complete mid-2023.
Awarded up to $17.8M NIAID contract to develop epetraborole for melioidosis using non-dilutive funding.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss was $11.8 million and $41.0 million, respectively.

Period: the fourth quarter and year ended December 31, 2022
Net income: net loss was $11.8 million and $41.0 million, respectively
Result: reported results

Exact text from the filing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.